[Lipidology update : Evidence-based treatment of dyslipidemia]

Area of Science:

• Cardiology
• Metabolic Disorders
• Preventive Medicine

Background:

• Elevated plasma lipids, particularly low-density lipoprotein (LDL) cholesterol and triglycerides, are significant risk factors for atherosclerosis.
• Current guidelines emphasize LDL cholesterol reduction for cardiovascular disease prevention, with statins as a cornerstone therapy.
• The role and treatment targets for elevated triglycerides remain less defined despite their causal link to atherosclerotic events.

Purpose of the Study:

• To outline the importance of lipid-lowering therapy in atherosclerosis prevention.
• To define treatment goals for LDL cholesterol based on absolute cardiovascular risk.
• To discuss the role of lifestyle modification and pharmacotherapy in managing elevated triglycerides.

Main Methods:

• Review of current clinical guidelines and evidence regarding lipid management.
• Emphasis on risk stratification to determine the intensity of lipid-lowering therapy.
• Discussion of the efficacy of lifestyle modifications versus pharmacological interventions for LDL and triglyceride reduction.

Main Results:

• Achieving very low LDL cholesterol levels (<55 mg/dl) and a 50% reduction is recommended for very high-risk patients.
• Lifestyle modification is a minor factor in LDL cholesterol lowering but can significantly reduce triglyceride levels.
• The effectiveness of new lipid-lowering drugs requires further validation through endpoint trials.

Conclusions:

• Aggressive LDL cholesterol lowering is paramount in atherosclerosis prevention, guided by absolute cardiovascular risk.
• While lifestyle changes are less impactful for LDL reduction, they are effective for managing elevated triglycerides.
• Further research and clinical trials are necessary to establish the benefits of novel lipid-lowering agents.